Combined reports on serum calcium and discriminant functions increase the diagnostic rate of hypercalcaemia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 8, 1997, Pages 725-729

  Frolich A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Malignancy; Primary hyperparathyroidism; Transient hypercalcaemia

Indexed keywords

ARTICLE; CALCIUM BLOOD LEVEL; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031450019     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709105235     Document Type: Article

References (15)

1. Frølich A, McNair P, Transbøl I. Awareness of hypercalcaemia in a hospital population? Scand J Clin Lab Invest 1991; 51: 37-41.
2. Link K, Centor R, Buchsbaum D, Winterspoon J. Why physicians don't pursue abnormal laboratory tests: An investigation of hypercalcemia and the follow-up of abnormal test results. Human Pathol 1984; 15: 75-8.
3. Rajathurai A, Cove-Smith R. Hypercalcaemia in Cleveland: a hospital-based survey. J Roy Soc Med 1984; 77: 742-6.
4. Dent DM, Miller JL, Klaff L, Barron J. The incidence and causes of hypercalcaemia. Postgrad Med J 1987; 63: 745-50.
5. Diamond TH, Botha JR, Vermaak WJH, Kalk WJ. Hypercalcaemia in the Johannesburg Hospital. Differential diagnosis and physician awareness of primary hyperparathyroidism. S Afr Med J 1987; 72: 113-5.
6. McDonald CJ, Hui SL, Smith DM, Tierney WM, Cohen SJ, Weinberger M, McCabe GP. Reminders to physicians from an introspective computer medical record. Ann Intern Med 1984; 100: 130-8.
7. Frølich A, Nielsen BF, Conradsen K, McNair P. Filtering clinically significant hypercalcemia from non-significant hypercalcemia at the laboratory level. Scand J Clin Lab Invest 1993; 53: 215-23.
8. Hedbäck G, Oden A. Clinical evaluation of total serum calcium in primary hyperparathyroidism and the risk of death after surgery. Eur J Clin Invest 1995; 25: 48-52.
9. Bajorunas DR. Disorders of endocrine function in the critically ill cancer patient. In: Howland WS, Carlon GC, editors. Critical care of the cancer patient. Chicago: Year Book Medical, 1985: 143-72.
10. Myers WPL. Hypercalcemia associated with malignant diseases. In: Endocrine and nonendocrine hormone-producing tumors. Chicago: Year Book Medical, 1973: 147-71.
11. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
12. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990; 112: 499-504.
13. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone 1991; 12 Suppl 1: S37-S42.
14. Frølich A, Nielsen BF, Conradsen K, McNair P, Transbøl I. Within-centre evaluation of hypercalcemia discriminant functions five years after their development. Int J Biomed Comput 1996; 40: 235-40.
15. Frølich A, Nielsen BF, Nielsen J, Conradsen K, McNair P. Do local hospitals meet the analytical goals for the use of common reference intervals? Scand J Clin Lab Invest 1994; 54: 169-76.